ey0019.10-17 | New treatments | ESPEYB19
T Fuselier
, de Sa P Mota
, MMF Qadir
, B Xu
, C Allard
, MM Meyers
, JP Tiano
, BS Yang
, V Gelfanov
, SH Lindsey
, RD Dimarchi
, F Mauvais-Jarvis
Cell Rep Med 2022;3:100598. https://pubmed.ncbi.nlm.nih.gov/35492248/Brief Summary: This study used a combination of mice models and cultured human islets to show that a glucagon-like peptide-1 (GLP-1) and estrogen (E2) dual agonist (GLP1-E2) provides superior protection from insulin-deficient diabetes compared to GLP-1 and E2 monoagonists. Pancreatic islet protection...